Florian Muller, Ph.D.
Cancer Systems Imaging
The Muller lab’s near-term career goal is to develop a small-molecule Enolase inhibitor for in vivo proof-of-principal, and ultimately, as a clinical candidate for the treatment of cancers which harbor deletions of ENO1. The secondary goal is to demonstrate the universality and expand the utility of this therapeutic strategy to other passenger deleted genes. Their tertiary goals are to use genomic deletions in cancer to gain insight into the basic biochemistry and metabolism of human cancer, as well as to utilize this knowledge for imaging purposes.
Muller’s team proposed a novel strategy for molecular targeted therapy in cancer, exploiting vulnerabilities exposed by passenger deleted genes, termed “collateral lethality”. His group presented proof-of-principal data for one example of this strategy, where glioma cells with passenger deletion of the glycolytic enzyme, ENO1 are selectively sensitive to inhibition to its redundant homologue, ENO2.
With an innate curiosity and strong satisfaction from basic discovery, their outlook is strongly translational, with success being measured by whether or not a compound is brought to the clinic.
Principal Investigator, 2.4 months, Institutional Start-up Research Funding, The University of Texas MD Anderson Cancer Center, 10/30/2014-10/2/2019, $150,000
Principal Investigator, 2.4 months, Passenger Deletion of ENO1 as a Targetable Vulnerability in Cancer, RSG-15-145-01-CDD, American Cancer Society (ACS), 1/1/2016-12/31/2019, $765,000 ($165,000/year)
Co-Principal Investigator, 0.12 months, In Vivo Molecular Breast Imaging with TC 99M Sestamibi for the Prediction of Multidrug Resistance in Triple Negative Breast Cancers, CABI/GE In-Kind Research Grant, CABI/GE IN-KIND Research Grant Multi-Investigator Imaging (M12) Research Award, PI - Rauch, 4/1/2016-3/31/2021, $264,392
Principal Investigator, 0.12 months, Rising STARS Award (Muller), The University of Texas, 12/1/2016-11/30/2019, $250,000
Principal Investigator, 1.44 months, ENO1-deletion as a target for personalized oncology: Collateral Lethality to the Clinic, National Comprehensive Cancer Network – Young Investigator Award, 7/1/2017-6/30/2019, $71,023
Co-Principal Investigator, 1.2 months, Collateral Lethality of PTEN Deleted Castration Resistant Prostate Cancer, UT MD Anderson SPORE in Prostate Cancer – Developmental Research Project, 9/1/2017-8/31/2018, $50,000
Co-Principal Investigator, 0.6 months, Collateral Lethality Targeting of PTEN Deletion in Glioblastoma, 2P50CA127001, UT MD Anderson SPORE in Brain Cancer – Developmental Research Project, 9/1/2017-8/31/2018, $50,000
Principal Investigator, 3 months, Collateral Deletion of PANK1 as a Therapeutically Targetable Vulnerability in PTEN-Deleted Cancers, Elsa U Pardee Foundation, 1/1/2018-12/31/2018, $156,314 ($156,314/year)
Principal Investigator, Collateral Lethality Based Tumor Eradication via T-cell Activation, Institution Research Grant (IRG), 1/1/2018-12/31/2018, $75,000 ($75,000/year)
Principal Investigator, 2.4 months, Pro-drug Moieties for the Tumor Specific Delivery of STING-agonist Immunostimulants, Peter Bradley Carlson Charitable Trust (Frost Bank), 1/1/2018-12/31/2018, $28,000 ($28,000/year)
Principal Investigator, 1.2 months, Tumors with 1p36 Homozygous Deletions Constitute a Rare, Phenotypically Distinct Cancer, Uniquely Sensitive to Inhibition of the Glycolytic Enzyme Enolase, Harrington Discovery Institute, 3/1/2018-2/28/2020, $75,000
Principal Investigator, 3 months, Collateral Deletions Expose Targetable Metabolic Vulnerabilities in the PTEN locus, PAR-16-176, NIH/NCI, 4/1/2018-3/31/2020, $150,000
Principal Investigator, 2.4 months, Collateral Lethality mediated tumor eradication by T-cell activation, Andrew Sabin Family Foundation Fellows Award, 4/1/2018-3/31/2020, $100,000
Principal Investigator, 0.6 months, A novel glycolysis inhibitor for B-Cell leukemia and lymphoma, Ladies Leukemia League, 6/1/2018-5/31/2019, $30,000 ($30,000/year)
Principal Investigator, 3 months, Collateral Lethality-based tumor eradication by T-Cell Activation, NIH/NCI, 7/1/2018-6/30/2022, $1,133,414
Principal Investigator, 3 months, Pro-Drug Enolase Inhibitors in Precision Oncology, PA-16-160, NIH/NCI, 7/1/2018-6/30/2023, $1,691,628
Co-Investigator, 3 months, Collateral Genomic Deletions As Targetable Vulnerabilities in Cancer, RP140612, Cancer Prevention & Research Institute of Texas (CPRIT), PI - DePinho, 8/31/2014-8/30/2017, $285,000
Co-Principal Investigator, 3 months, Development of an Enolase inhibitor for 1p36 homozygously deleted GBM, NIH/NCI, PI - Lang, Fueyo, 9/1/2014-8/31/2016, $50,000
Co-Principal Investigator, 1.8 months, Nerstian Probes as Vectors for Imaging and Therapeutic Modalities in Glioblastoma, NIH/NCI, PI - Lang, Fueyo, 9/1/2015-8/31/2016, $50,000
The University of Texas MD Anderson Cancer Center
Cancer Systems Imaging
1881 East Road
Unit Number: 1907
Room Number: 3SCR4.3620
Houston, TX 77054-1901